Table 4.

Cause-specific mortality in patients with dementia by diabetes status

	Diabetes and dementia sHR (95% CI)				Diabetes-free and dementia sHR (95% CI)
	Cardiovascular mortality		Diabetes mortality		Cardiovascular mortality
	Model 0	Model 1	Model 0	Model 1	Model 0	Model 1
Whole cohort
ChEI	0.60 (0.49 to 0.73)**	0.87 (0.69 to 1.08)	0.46 (0.29 to 0.72)*	0.52 (0.32 to 0.87)*	0.53 (0.48 to 0.58)**	0.77 (0.69–0.85)**
Donepezil	0.66 (0.51 to 0.84)*	0.84 (0.65 to 1.08)	0.51 (0.29 to 0.92)*	0.56 (0.30 to 1.05)	0.61 (0.54 to 0.68)**	0.73 (0.65–0.82)**
Rivastigmine	0.66 (0.45 to 0.96)*	0.83 (0.57 to 1.22)	0.40 (0.15 to 1.09)	0.46 (0.16 to 1.30)	0.59 (0.49 to 0.70)**	0.78 (0.65–0.93)*
Galantamine	0.88 (0.66 to 1.17)	1.11 (0.83 to 1.49)	0.73 (0.38 to 1.40)	0.81 (0.42 to 1.58)	0.72 (0.63 to 0.83)**	0.98 (0.86–1.13)

	Diabetes and dementia sHR (95% CI)		Diabetes-free and dementia sHR (95% CI)
	Cardiovascular mortality	Diabetes mortality	Cardiovascular mortality
PS matched
ChEI	1.02 (0.80 to 1.30)	0.87 (0.54 to 1.39)	0.92 (0.81 to 1.02)
Donepezil	0.89 (0.69 to 1.14)	0.77 (0.47 to 1.27)	0.84 (0.75 to 0.94)*
Rivastigmine	0.83 (0.56 to 1.24)	0.92 (0.36 to 2.32)	1.06 (0.88 to 1.26)
Galantamine	1.10 (0.79 to 1.54)	0.89 (0.44 to 1.80)	1.05 (0.90 to 1.23)

Model 0 was unadjusted; Model one was adjusted for age at dementia diagnosis, gender, dementia type, cohabitation, Mini-Mental State Examination score, antipsychotics, hypnotics/sedatives, cardiovascular and antithrombotic medication and Charlson comorbidity index; Model one for the analysis in patients with diabetes and dementia was additionally adjusted for the use of antidiabetic medication and diabetes duration; PS-matched analysis of ChEI is adjusted for age and MMSE in the Diabetes-Free cohort and age and dementia type in the Diabetes cohort due to residual differences in the matched cohorts.

*P<0.05; **P<0.001.

ChEI, cholinesterase inhibitors; sHR, subdistribution HR; PS, propensity score.